Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The firm’s products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.